Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: somethingwicked who wrote (276)	9/30/2000 9:14:30 AM
From: flatsville	Read Replies (3) \| Respond to of 340

Yes, watching volume is important. We'll bust $80 (with some profit taking-today for example.) There's a lot of money looking for a home outside of tech, but still on the NAZ (as someone recently said rotation, rotation, rotation instead of location, location, location.) TEVA is a good defensive play...and I think it will do well no matter which candidate wins the election.

To: somethingwicked who wrote (276)	8/15/2001 6:49:36 AM
From: Dorine Essey	Read Replies (1) \| Respond to of 340

I hope you have been holding your TEVA? Teva ((TEVA.O)) Launches $300 Mln 20-yr Convertible August 15, 2001 06:35:14 (ET) JERUSALEM, Aug 15 (Reuters) - Israeli generic drug maker Teva Pharmaceutical Industries said on Wednesday its unit, Teva Pharmaceutical Finance N.V., launched its offering of $300 million of 0.75 percent 20-year convertible senior notes. The notes will be convertible into Teva's American Depositary Receipts (ADRs) at a conversion price of $85.824 per ADR, reflecting a premium of 28 percent from Tuesday's closing share price of $67.05.